Knopp Biosciences to eliminate paper source documents at investigator sites by utilizing novel eSource platform
Online PR News – 02-July-2012 – Horsham, PA – Clinical Ink, the pioneering provider of eSource solutions for clinical trials, announced today that Knopp Biosciences LLC of Pittsburgh, PA, has agreed to use Clinical Ink’s SureSource® platform in a planned clinical study of a novel combination treatment for Parkinson’s disease. Knopp will conduct the study as an eSource project with subject data collected electronically during the subject visit, which will allow monitoring of the data remotely almost immediately after collection in the clinic.
“We are pleased to partner with Knopp Biosciences in support of their clinical objectives by leveraging the SureSource platform to deliver clinical results more affordably, more confidently, and more quickly than existing technology approaches,” commented Ed Seguine, CEO of Clinical Ink. “The Clinical Ink approach to eSource shifts the focus of clinical trial data collection to the point of care – during the subject visit. Doing so dramatically simplifies the entire clinical trial process and our early customers have seen remarkable results: validated data available within 30 minutes, 70% of monitoring activity performed remotely, and sites that actually want to use technology because it improves their work, too.”
As a recent Gartner report points out, Clinical Ink “has significant disruptive potential . . . to eliminate steps and streamline the clinical study data capture process” (see www.clinicalink.com/gartner2012). This transformative approach has far-reaching implications for sites, sponsors, and CROs. Importantly, the FDA is actively encouraging and promoting change with the recent eSource and Risk-Based Monitoring draft guidance documents.
About Clinical Ink, Inc.
Clinical Ink has pioneered the development of eSource technology for use in clinical trials. SureSource® replaces paper source documents and CRFs with intuitive electronic forms that maintain the natural workflow, ease of use, and mobility of paper chart. Unlike EDC systems, our approach to eSource captures/validates data during the subject visit. As a result, data queries are dramatically reduced, source data verification is eliminated, monitoring is performed real-time and remotely, and validated clinical data is available within minutes. Clinical Ink has offices in Philadelphia and Winston-Salem. For more information visit www.clinicalink.com or call 800-301-5033.